![]() |
|||||||||||
Member InformationPablo Tebas, MD Office Phone: 215-615-4321 Education: MD 1986, Universidad Autonoma de Madrid ( Spain ) Keywords: HIV therapeutics, metabolic complications, immunomodulators Summary: Representative Publications: Tebas, P; Henry, K; Mondy; K; Deeks, S; Valdez, H; Cohen, C; Powderly, WG. Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4+ T Cell Decline in HIV-infected Patients: Implications for Intermittent Therapeutic Strategies. Journal of Infectious Diseases 2002; 186: 851-854. Ristig, MB; Crippin, J; Aberg, JA; Powderly, WG; Lisker-Melman, M; Kesssels, L; Tebas, P. Tenofovir-DF Therapy for Chronic Hepatitis B in HIV/HBV Co-Infected Individuals Who have Failed Interferon-alpha and Lamivudine. Journal of Infectious Diseases 2002;186:1844-7 Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17:513-20. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-90. |
|||||||||||
|
|||||||||||
![]() |
|||||||||||